Skip to content

Safety Evaluation of ExAblate MRgFUS for Prostate Cancer

Safety, Compatibility and Imaging Quality of ExAblate Prostate Applicator for Prostate Cancer

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00811265
Enrollment
10
Registered
2008-12-18
Start date
2009-01-31
Completion date
2013-06-30
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

ExAblate MRgFUS, Focused ultrasound, Magnetic resonance imaging, Prostate cancer, Radical prostatectomy candidate

Brief summary

Evaluate the safety, compatibility and imaging quality of the ExAblate MRgFUS system.

Detailed description

The objective of this study is to evaluate safety, compatibility and imaging quality of the ExAblate MRgFUS system for prostate cancer, under simulated use conditions. No acoustic energy will be delivered and no focused ultrasound therapy will be performed. This is an imaging only study.

Interventions

DEVICEExAblate MRgFUS for prostate cancer

Simulated use of ExAblate MRgFUS system

Sponsors

InSightec
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
No minimum to 75 Years
Healthy volunteers
No

Inclusion criteria

* Age of patients: up to 75 years. * Men scheduled for radical prostatectomy due to prostate cancer. * Patients who are able and willing to give consent and able to attend all study visits.

Exclusion criteria

* Contraindications to MRI including: claustrophobia, weight over 120 kg, implanted ferromagnetic materials or foreign objects, and known intolerance to the MRI contrast agent (e.g. Gadolinium or Magnevist) * Severely abnormal coagulation (INR\>1.5) * Patients with unstable cardiac status including: unstable angina pectoris on medication, patients with documented myocardial infarction within six months of protocol entry, congestive heart failure requiring medication (other than diuretic), patients on anti-arrhythmic drugs, severe hypertension (diastolic BP \> 100 on medication), and patients with cardiac pacemakers * Severe cerebrovascular disease (multiple CVA or CVA within 6 months) * Individuals who are not able or willing to tolerate the required prolonged stationary supine position during imaging (approximately 1 hrs.) * Any rectal pathology preventing probe insertion, (as active proctitis, ulcerative colitis, fissure ani, diverticulitis, previous rectal surgery, IBD, etc…) * Any spinal pathology that prohibits maintaining supine position for more then an hour * Any previous radiation to the pelvis.

Design outcomes

Primary

MeasureTime frame
Device-related adverse eventsThroughout study period

Secondary

MeasureTime frame
Device compatibility with human anatomyDuring simulated device use
MR Imaging QualityDuring simulated device use

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026